From publications to every day clinical practice: tocilizumab in patients with severe COVID-19.

Introduction: there is evidence on the effectiveness and safety of tocilizumab (TZC) used in combination with systemic corticosteroids for severe SARS-CoV-2 pneumonia treatment. The purpose of this study was to describe epidemiological, clinical, and laboratory features as well as clinical outcome of patients receiving this combination therapy compared with those receiving only corticosteroids.

Methods: a retrospective cohort study, which included adults with severe SARS-CoV-2 pneumonia, was conducted between March and August 2021.